PRVB News and Press, Provention Bio Inc. From 09/30/20

Provention Bio (PRVB) reports that it has filed the clinical module of its rolling U.S. marketing application for teplizumab (PRV-031) for the delay or prevention of type 1 diabetes (T1D) in at-risk people.It initiated the process in April with the submission of the nonclinical module. It exp...

Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals - Expect to complete filing of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 - PR Newswire RED BANK, ...

Gainers: [[SPI]] +58.3%. [[MCHX]] +16.1%. [[JEF]] +8.9%. [[PRVB]] +8.8%. [[DPW]] +3.5%.Losers: [[WNC]] -3.5%. [[PEAK]] -3.3%. [[ICPT]] -2.8%. [[NNOX]] -2.4%. [[BEKE]] -2.2%. For further details see: SPI, JEF, PEAK and ICPT among after-hours movers

RED BANK, N.J. , Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at three upcoming virtual investor conferences in September: ...

Provention Bio ( PRVB +1.1% ) announced the initiation of the Phase 2b PROACTIVE study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as ' Non-Responsive Celiac Disease '. More news on: Provent...

OLDWICK, N.J. , Aug. 31, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2b PROACTIVE ( PRO vention  A mgen  C eliac Protec ...

SEATTLE , Aug. 25, 2020 /PRNewswire/ -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), achieved the on-schedule completion of a drug substance Process Performance Qualification (PPQ) campaign, focused on teplizumab  (...

Here's a simple argument for why long-term investors should consider buying shares of biotech companies. Since its inception in 2006, the SPDR S&P Biotech Index  -- an industry benchmark -- has crushed the S&P 500 , as the graph below shows. ^SPX data by YCharts Continu...

OLDWICK, N.J. , Aug. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of John K. Jenkins, MD to the Company's Board of Directors. Prior...

Provention Bio, Inc. (PRVB) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 ET Company Participants Andrew Drechsler - CFO Ashleigh Palmer - Co-Founder, President, CEO & Director Jason Hoitt - Chief Commercial Officer Francisco Leon - Co-Founder & Chief Scientif...